Morgan Stanley: 'we see Amvuttra as well positioned'
March 24, 2026 3:08 PM
Morgan Stanley analyst Andrew Galler reiterated an Equalweight rating and $360.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
